Impact Of Patent Expirations On The Biosimilars Market For Adalimumab, Infliximab, And Etanercept: Powering Innovation and Expansion in the Adalimumab, Infliximab and Etanercept Biosimilars Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Adalimumab, Infliximab and Etanercept Biosimilars Market Through 2025?
The market size of biosimilars such as adalimumab, infliximab, and etanercept has seen fast-paced growth in the preceding years. The market which is valued at $4.37 billion in 2024 is expected to expand to $4.98 billion in 2025, recording a compound annual growth rate (CAGR) of 14.1%. The driving forces behind the growth experienced in the historical period are the rise in health care spending, modifications of regulations, government interventions, and escalating healthcare costs.

What's the Projected Size of the Global Adalimumab, Infliximab and Etanercept Biosimilars Market by 2029?
The biosimilars market for adalimumab, infliximab and etanercept is predicted to experience a notable rise in the coming years, reaching a market size of $7.44 billion by 2029 with a compound annual growth rate of 10.5%. Factors contributing to this predicted growth during the forecast period include increased healthcare spending, aging populace, and enhanced healthcare accessibility. The primary trends expected for this period include emphasis on introducing fresh products, focus on consolidation through mergers and acquisitions, endeavors towards forging strategic alliances, and dedication towards escalating investments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Top Growth Drivers in the Adalimumab, Infliximab and Etanercept Biosimilars Industry: What's Accelerating the Market?
The possibility for biosimilars of adalimumab, infliximab, and etanercept to penetrate the market is made possible with the patent expiration of name-brand drugs. For example, in the United States, Inflectra, a product of Hospira (which is part of Pfizer Inc.), received FDA approval for use in treating several autoimmune diseases including rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, following the patent end for the name-brand drug, Remicade. Similarly, the EU patent for Amgen's Enbrel expired, and consequently, Benepali, a biosimilar of Enbrel, received endorsement by the European Commission. The patent for Humira also ended, and as a result, its biosimilars found their way into the marketplace. Hulio, the sixth biosimilar of Humira, was recently given approval by the FDA. Thus, the patent terminations of branded biologic drugs like Humira, Enbrel, and Remicade are set to stimulate demand and growth in the adalimumab, infliximab, and etanercept biosimilars market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Trends Will Shape the Adalimumab, Infliximab and Etanercept Biosimilars Market Through 2029 and Beyond?
Leaders in the adalimumab, infliximab, and etanercept biosimilars market, such as Fresenius Kabi, are putting their resources into creating innovative products like citrate-free adalimumab, which offers reliable solutions to consumers. In the pharmaceutical world, citrate-free adalimumab stands out because it's a version of the biological medicine adalimumab that doesn't contain citrate. In an exemplary move in December 2022, the Germany-based medical technology and medicine manufacturing company, Fresenius Kabi, received FDA approval for its biosimilar product- Idacio (adalimumab). This product, designed for managing all approved uses of chronic autoimmune disorders, deploys cutting-edge analytical methods and offers promising treatment for a variety of chronic diseases.

What Are the Main Segments in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented -

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Which Top Companies are Driving Growth in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Which Regions Will Dominate the Adalimumab, Infliximab and Etanercept Biosimilars Market Through 2029?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.